查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1830979

药物研发服务市场

Drug Discovery Services Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

药物研发服务市场规模预计将从 2024 年的 255.1 亿美元增加到 2031 年的 648.9 亿美元，2025 年至 2031 年的预估复合年增长率为 14.3%。

市场洞察与分析师观点：药物发现是指识别或创造旨在治疗疾病和增进人类健康的新药的过程。该过程包括透过合成、实验室测试、动物模型评估和人体试验等各个阶段来识别潜在的候选药物。药物发现服务提供者提供专业知识和资源来促进药物发现过程，其中可能包括药物化学、计算建模、高通量筛选和临床前测试服务。这些服务通常由合约研究组织 (CRO) 或学术研究机构提供。製药公司和生技公司利用这些服务来加快药物发现流程，同时保持效率。

成长动力与挑战：受各治疗领域对创新疗法日益增长的需求所推动，药物研发服务市场正经历大幅成长。药物研发过程复杂且漫长，其成功依赖对潜在候选药物的全面研究以及测试和验证。因此，製药公司和研究机构越来越依赖药物研发服务提供者来支持其药物开发计画。这些服务提供者提供标靶识别和验证、先导化合物优化、临床前研究以及药物动力学和毒理学测试等重要服务。此外，生物技术和製药公司正致力于开发针对个别患者特定基因和分子特征的标靶治疗方案，从而促进更个人化的医疗保健。精准医疗和个人化治疗的日益普及进一步推动了对药物研发服务的需求。

製药公司不断增加的研发投入，加上高通量筛选、计算建模和人工智慧等先进技术的普及，也为药物研发服务市场带来了利多。这些技术促进了更有效率、更有效的药物研发流程，从而提高了新药的上市成功率。新药的研发成本高昂，通常需要在研发和临床试验方面投入大量资金。根据《基因工程与生物技术》杂誌的研究，去年全球排名前20的生物製药公司新药研发平均成本上涨了15%（2.98亿美元），达到近23亿美元。

临床试验后期候选药物的高失败率进一步推高了药物开发的整体成本。因此，製药和生物技术公司日益寻求经济高效的药物发现服务，这促使服务提供者在维持高品质标准的同时提供具有竞争力的价格。药物分子的高昂成本也影响了患者对新疗法的可负担性，尤其是在罕见疾病或利基治疗领域，这对药物开发商和医疗保健系统在确保创新疗法的可及性方面都构成了重大挑战。

策略洞察报告细分和范围：药物发现服务市场根据流程、类型、分子类型、治疗领域和最终用户进行分类。就流程而言，市场分为目标选择和验证、先导化合物识别和其他（例如检测开发和筛选）。按类型划分，药物发现服务市场分为生物服务、药物化学、药物代谢和药物动力学。就分子类型而言，市场分为生物製剂和小分子。依治疗领域，市场细分为心血管疾病、肿瘤学、神经科、糖尿病、呼吸系统疾病等。按最终用户划分，市场分为製药和生物技术公司、学术机构和其他。从地理上看，药物发现服务市场分为北美（美国、加拿大和墨西哥）、欧洲（英国、德国、法国、义大利、西班牙和欧洲其他地区）、亚太地区（中国、日本、印度、韩国、澳洲和亚太其他地区）、中东和非洲（阿联酋、沙乌地阿拉伯、南非和中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲其他地区）。

細項分析：依分子类型划分，小分子药物在药物研发服务市场中占据较大收入份额。小分子药物市场的成长得益于其研究简单、特性明确且易于表征。

2022年，按类型划分，药物化学领域占据了药物发现服务市场的最大份额。药物化学广泛应用于药物发现的各个方面，从候选药物的递送到临床前研究。

就治疗领域而言，肿瘤学领域在2022年引领了药物研发服务市场。该领域的成长与全球在癌症相关药物研发方面不断增加的投入息息相关。由于一般人群中各种癌症的发生率不断上升，肿瘤学市场正在不断扩张。国际癌症研究机构估计，2020年全球约有1,000万人死于癌症，新增癌症病例1,930万例。预计2020年至2040年，全球新增癌症病例将成长47%，到2040年全球新增癌症病例预计将达到2,840万例。

药物发现服务市场报告范围：区域分析：从地理上看，药物发现服务市场主要分布在北美、欧洲、亚太地区、中东和非洲以及南美和中美。北美是全球市场成长的最大贡献者，这得益于药物开发公司的投资、美国政府的大量拨款、大型药物开发公司的强大影响力、完善的医疗基础设施以及慢性病发病率的上升。

美国癌症协会发布的《2022年癌症事实与数据》估计，到2022年底，美国将新增约1,918,030例癌症病例，并有609,360例癌症相关死亡病例。鑑于该地区癌症发生率高，预计未来几年美国抗癌药物创新研究活动将蓬勃发展。 2022年9月，CytoReason与辉瑞达成多年期合作，辉瑞将运用CytoReason的人工智慧技术进行药物开发。美国主要公司将人工智慧技术融入药物研发领域，预计将推动药物研发服务市场的成长。

预计2022年至2030年，亚太地区药物研发服务市场的复合年增长率将达到最高。该地区的成长得益于中国、印度、日本和韩国等国家对研发活动的投入不断增加，这些国家正逐渐成为製药和生物技术的重要枢纽。此外，亚太地区拥有大量高技能的研究人员和科学家，且营运成本低于西方国家，使其成为药物研发服务外包的理想目的地。慢性病盛行率的上升以及对创新药物以满足未满足医疗需求的需求，进一步推动了该地区药物研发服务市场的成长。

竞争格局和主要公司：药物研发服务市场的主要参与者包括安捷伦科技、Ubiquigent、雅培实验室、Advinus Therapeutics、Albany Molecular Research Inc.、Aurigene、拜耳公司、阿斯利康公司、Charles River Laboratories International、Covance 和 ChemBridge Corporation。这些公司致力于扩展其服务范围，以满足日益增长的全球需求。其国际影响力使其能够满足广泛的客户群，从而提升其市场份额。

目录

第一章：简介

第 2 章：执行摘要

  • 关键见解
  • 市场吸引力分析

第三章：研究方法

第四章：药物研发服务市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链中的供应商列表

第五章：药物研发服务市场－关键市场动态

  • 关键市场驱动因素
  • 主要市场限制因素
  • 关键市场机会
  • 未来趋势
  • 驱动因素和限制因素的影响分析

第六章：药物研发服务市场－全球市场分析

  • 药物研发服务 - 全球市场概览
  • 药物研发服务－全球市场及2030年预测

第七章：药物研发服务市场-收入分析-依流程，2020-2030

  • 概述
  • 目标选择和验证
  • 线索识别
  • 其他的

第八章：药物研发服务市场-收入分析-按类型，2020-2030

  • 概述
  • 生物学服务
  • 药物化学
  • 药物代谢和药物动力学

第九章：药物研发服务市场-收入分析-依分子型，2020-2030

  • 概述
  • 生物製剂
  • 小分子

第 10 章：药物发现服务市场 - 收入分析 - 按治疗领域，2020-2030 年

  • 概述
  • 心血管疾病
  • 肿瘤学
  • 神经病学
  • 糖尿病
  • 呼吸系统疾病
  • 其他的

第 11 章：药物发现服务市场 - 收入分析 - 按最终用户，2020-2030 年

  • 概述
  • 製药和生物技术公司
  • 学术机构
  • 其他的

第 12 章：药物发现服务市场 - 收入分析，2020-2030 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第十三章：新冠疫情前后的影响

第 14 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 15 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第 16 章：药物研发服务市场 - 主要公司简介

  • Abbott Laboratories
  • Agilent Technologies
  • Ubiquigent
  • Albany Molecular Research Inc.
  • AstraZeneca PLC
  • Aurigene
  • Bayer AG
  • Charles River Laboratories International
  • ChemBridge Corporation
  • Covance

第 17 章：附录

简介目录
Product Code: TIPRE00003410

The drug discovery services market size is expected to increase from US$ 25.51 billion in 2024 to US$ 64.89 billion by 2031, with a projected CAGR of 14.3% from 2025 to 2031.

Market Insights and Analyst View:Drug discovery refers to the process of identifying or creating new medications aimed at treating diseases and enhancing human health. This process encompasses the identification of potential drug candidates through various stages, including synthesis, laboratory testing, animal model evaluation, and human trials. Providers of drug discovery services offer specialized knowledge and resources to facilitate the drug discovery process, which may include medicinal chemistry, computational modeling, high-throughput screening, and preclinical testing services. These services are typically offered by contract research organizations (CROs) or academic research institutions. Pharmaceutical companies and biotechnology firms utilize these services to expedite drug discovery processes while maintaining efficiency.

Growth Drivers and Challenges:The drug discovery services market is witnessing substantial growth driven by the increasing demand for innovative therapies across various therapeutic areas. The drug discovery process is intricate and lengthy, with its success relying on comprehensive research into potential drug candidates, along with their testing and validation. Consequently, pharmaceutical companies and research institutions are increasingly depending on drug discovery service providers to bolster their drug development initiatives. These providers offer essential services such as target identification and validation, lead optimization, preclinical studies, and pharmacokinetic and toxicology testing. Additionally, biotechnology and pharmaceutical companies are striving to create targeted treatments that cater to the specific genetic and molecular profiles of individual patients, promoting a more personalized healthcare approach. This growing emphasis on precision medicine and personalized therapies further drives the demand for drug discovery services.

Rising R&D investments from pharmaceutical companies, coupled with the availability of advanced technologies like high-throughput screening, computational modeling, and artificial intelligence, are also advantageous for the drug discovery services market. These technologies facilitate more efficient and effective drug discovery processes, resulting in a higher success rate for new drug introductions. The process of discovering and developing new drugs is costly, often necessitating significant investments in research, development, and clinical trials. According to a study by Genetic Engineering & Biotechnology, the average cost of developing new medicines among the top 20 global biopharmaceuticals rose by 15% ($298 million) to nearly $2.3 billion last year.

The high failure rate of drug candidates in the later phases of clinical trials further escalates the overall cost of drug development. As a result, pharmaceutical and biotechnology companies are increasingly seeking cost-effective drug discovery services, prompting service providers to offer competitive pricing while upholding high-quality standards. The substantial cost of drug molecules also affects the affordability of new therapies for patients, particularly in the context of rare diseases or niche therapeutic areas, presenting a significant challenge for both drug developers and healthcare systems in ensuring access to innovative treatments.

Strategic Insights

Report Segmentation and Scope:The drug discovery services market is categorized based on process, type, molecule type, therapeutic area, and end user. In terms of process, the market is divided into target selection and validation, hit to lead identification, and others (such as assay development and screening). By type, the drug discovery services market is segmented into biology services, medicinal chemistry, drug metabolism, and pharmacokinetics. Regarding molecule type, the market is classified into biologics and small molecules. Based on therapeutic areas, the market is segmented into cardiovascular diseases, oncology, neurology, diabetes, respiratory diseases, and others. By end user, the market is divided into pharmaceutical and biotechnology companies, academic institutions, and others. Geographically, the drug discovery services market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:The small molecules segment accounted for a larger revenue share of the drug discovery services market, based on molecule type. The growth of the small molecules market is attributed to their simplicity in study, well-defined characteristics, and ease of characterization.

In 2022, the medicinal chemistry segment held the largest share of the drug discovery services market by type. Medicinal chemistry is extensively utilized in various aspects of drug discovery, from candidate delivery to preclinical studies.

In terms of therapeutic area, the oncology segment led the drug discovery services market in 2022. The growth of this segment is linked to the increasing global efforts in cancer-related drug discovery. The oncology market is expanding due to the rising incidence of various cancers among the general population. The International Agency for Research on Cancer estimated approximately 10 million cancer-related deaths and 19.3 million new cancer cases in 2020. The global number of new cancer cases is projected to rise by 47% from 2020 to 2040, leading to an estimated 28.4 million new cancer cases worldwide by 2040.

Drug Discovery Services Market Report Scope

Regional Analysis:Geographically, the drug discovery services market is primarily segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the largest contributor to the growth of the global market, driven by investments from drug development companies, substantial grants from the US government, a strong presence of major drug development firms, a well-established healthcare infrastructure, and an increase in chronic disease incidences.

The American Cancer Society's "Cancer Facts & Figures 2022" estimated around 1,918,030 new cancer cases and 609,360 cancer-related deaths in the US by the end of 2022. Given the high cancer rates in this region, research activities aimed at innovating cancer drugs are expected to thrive in the US in the coming years. In September 2022, CytoReason and Pfizer entered into a multi-year collaboration, allowing Pfizer to utilize CytoReason's artificial intelligence technology for drug development. The integration of AI technology in drug discovery by major US companies is anticipated to drive the growth of the drug discovery services market.

Asia Pacific is projected to exhibit the highest CAGR in the drug discovery services market from 2022 to 2030. The growth in this region is attributed to increasing investments in research and development activities in countries like China, India, Japan, and South Korea, which are emerging as key hubs for pharmaceuticals and biotechnology. Additionally, the availability of a large pool of skilled researchers and scientists, along with lower operational costs compared to Western countries, makes Asia Pacific an appealing destination for outsourcing drug discovery services. The rising prevalence of chronic diseases and the demand for innovative medications to meet unmet medical needs are further propelling the growth of the drug discovery services market in the region.

Competitive Landscape and Key Companies:Key players in the drug discovery services market include Agilent Technologies, Ubiquigent, Abbott Laboratories Inc., Advinus Therapeutics, Albany Molecular Research Inc., Aurigene, Bayer AG, AstraZeneca PLC, Charles River Laboratories International, Covance, and ChemBridge Corporation. These companies are focused on expanding their service offerings to meet the growing global demand. Their international presence enables them to cater to a broad customer base, thereby enhancing their market share.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Drug Discovery Services Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Drug Discovery Services Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Drug Discovery Services Market - Global Market Analysis

  • 6.1 Drug Discovery Services - Global Market Overview
  • 6.2 Drug Discovery Services - Global Market and Forecast to 2030

7. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Process, 2020-2030

  • 7.1 Overview
  • 7.2 Target Selection and Validation
  • 7.3 Hit To Lead Identification
  • 7.4 Others

8. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Type, 2020-2030

  • 8.1 Overview
  • 8.2 Biology Services
  • 8.3 Medicinal Chemistry
  • 8.4 Drug Metabolism and Pharmacokinetics

9. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Molecule Type, 2020-2030

  • 9.1 Overview
  • 9.2 Biologics
  • 9.3 Small Molecules

10. Drug Discovery Services Market - Revenue Analysis (USD Million) - By Therapeutic Area, 2020-2030

  • 10.1 Overview
  • 10.2 Cardiovascular Diseases
  • 10.3 Oncology
  • 10.4 Neurology
  • 10.5 Diabetes
  • 10.6 Respiratory Diseases
  • 10.7 Others

11. Drug Discovery Services Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 11.1 Overview
  • 11.2 Pharmaceutical and Biotechnology Companies
  • 11.3 Academic Institutes
  • 11.4 Others

12. Drug Discovery Services Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 12.1 North America
    • 12.1.1 North America Drug Discovery Services Market Overview
    • 12.1.2 North America Drug Discovery Services Market Revenue and Forecasts to 2030
    • 12.1.3 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Process
    • 12.1.4 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Type
    • 12.1.5 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Molecule Type
    • 12.1.6 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Therapeutic Area
    • 12.1.7 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By End User
    • 12.1.8 North America Drug Discovery Services Market Revenue and Forecasts and Analysis - By Countries
      • 12.1.8.1 United States Drug Discovery Services Market
        • 12.1.8.1.1 United States Drug Discovery Services Market, by Process
        • 12.1.8.1.2 United States Drug Discovery Services Market, by Type
        • 12.1.8.1.3 United States Drug Discovery Services Market, by Molecule Type
        • 12.1.8.1.4 United States Drug Discovery Services Market, by Therapeutic Area
        • 12.1.8.1.5 United States Drug Discovery Services Market, by End User
      • 12.1.8.2 Canada Drug Discovery Services Market
        • 12.1.8.2.1 Canada Drug Discovery Services Market, by Process
        • 12.1.8.2.2 Canada Drug Discovery Services Market, by Type
        • 12.1.8.2.3 Canada Drug Discovery Services Market, by Molecule Type
        • 12.1.8.2.4 Canada Drug Discovery Services Market, by Therapeutic Area
        • 12.1.8.2.5 Canada Drug Discovery Services Market, by End User
      • 12.1.8.3 Mexico Drug Discovery Services Market
        • 12.1.8.3.1 Mexico Drug Discovery Services Market, by Process
        • 12.1.8.3.2 Mexico Drug Discovery Services Market, by Type
        • 12.1.8.3.3 Mexico Drug Discovery Services Market, by Molecule Type
        • 12.1.8.3.4 Mexico Drug Discovery Services Market, by Therapeutic Area
        • 12.1.8.3.5 Mexico Drug Discovery Services Market, by End User
  • 12.2 Europe
    • 12.2.1 Germany
    • 12.2.2 France
    • 12.2.3 Italy
    • 12.2.4 Spain
    • 12.2.5 United Kingdom
    • 12.2.6 Rest of Europe
  • 12.3 Asia-Pacific
    • 12.3.1 Australia
    • 12.3.2 China
    • 12.3.3 India
    • 12.3.4 Japan
    • 12.3.5 South Korea
    • 12.3.6 Rest of Asia-Pacific
  • 12.4 Middle East and Africa
    • 12.4.1 South Africa
    • 12.4.2 Saudi Arabia
    • 12.4.3 U.A.E
    • 12.4.4 Rest of Middle East and Africa
  • 12.5 South and Central America
    • 12.5.1 Brazil
    • 12.5.2 Argentina
    • 12.5.3 Rest of South and Central America

13. Pre and Post Covid-19 Impact

14. Industry Landscape

  • 14.1 Mergers and Acquisitions
  • 14.2 Agreements, Collaborations, Joint Ventures
  • 14.3 New Product Launches
  • 14.4 Expansions and Other Strategic Developments

15. Competitive Landscape

  • 15.1 Heat Map Analysis by Key Players
  • 15.2 Company Positioning and Concentration

16. Drug Discovery Services Market - Key Company Profiles

  • 16.1 Abbott Laboratories
    • 16.1.1 Key Facts
    • 16.1.2 Business Description
    • 16.1.3 Products and Services
    • 16.1.4 Financial Overview
    • 16.1.5 SWOT Analysis
    • 16.1.6 Key Developments
  • 16.2 Agilent Technologies
  • 16.3 Ubiquigent
  • 16.4 Albany Molecular Research Inc.
  • 16.5 AstraZeneca PLC
  • 16.6 Aurigene
  • 16.7 Bayer AG
  • 16.8 Charles River Laboratories International
  • 16.9 ChemBridge Corporation
  • 16.10 Covance

17. Appendix

  • 17.1 Glossary
  • 17.2 About The Insight Partners
  • 17.3 Market Intelligence Cloud